Curis Inc - Asset Resilience Ratio
Curis Inc (CRIS) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Curis Inc (CRIS) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Curis Inc's Asset Resilience Ratio has changed over time. See Curis Inc shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Curis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Curis Inc (CRIS) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Curis Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Curis Inc Industry Peers by Asset Resilience Ratio
Compare Curis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Curis Inc (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Curis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $41.27 Million | -- |
| 2023-12-31 | 38.37% | $29.65 Million | $77.28 Million | -22.23pp |
| 2022-12-31 | 60.60% | $65.97 Million | $108.85 Million | +13.86pp |
| 2021-12-31 | 46.75% | $75.87 Million | $162.30 Million | +27.72pp |
| 2020-12-31 | 19.03% | $38.88 Million | $204.36 Million | +4.46pp |
| 2019-12-31 | 14.56% | $5.11 Million | $35.11 Million | +12.87pp |
| 2018-12-31 | 1.70% | $634.00K | $37.37 Million | -28.04pp |
| 2017-12-31 | 29.74% | $21.94 Million | $73.80 Million | -2.21pp |
| 2016-12-31 | 31.94% | $18.45 Million | $57.75 Million | -19.76pp |
| 2015-12-31 | 51.70% | $49.10 Million | $94.97 Million | -15.38pp |
| 2014-12-31 | 67.08% | $42.00 Million | $62.61 Million | +6.79pp |
| 2013-12-31 | 60.29% | $48.59 Million | $80.59 Million | -0.86pp |
| 2012-12-31 | 61.15% | $42.79 Million | $69.98 Million | +60.66pp |
| 2011-12-31 | 0.49% | $235.91K | $48.18 Million | -64.22pp |
| 2010-12-31 | 64.71% | $32.77 Million | $50.65 Million | +14.91pp |
| 2009-12-31 | 49.79% | $17.98 Million | $36.10 Million | +3.04pp |
| 2008-12-31 | 46.76% | $18.69 Million | $39.98 Million | +2.04pp |
| 2007-12-31 | 44.71% | $24.06 Million | $53.82 Million | +10.61pp |
| 2006-12-31 | 34.11% | $17.83 Million | $52.27 Million | -1.84pp |
| 2005-12-31 | 35.95% | $21.90 Million | $60.91 Million | -3.72pp |
| 2004-12-31 | 39.67% | $26.83 Million | $67.63 Million | +26.37pp |
| 2003-12-31 | 13.30% | $7.41 Million | $55.74 Million | -2.16pp |
| 2002-12-31 | 15.46% | $9.65 Million | $62.44 Million | +6.36pp |
| 2001-12-31 | 9.10% | $13.17 Million | $144.76 Million | -3.30pp |
| 2000-12-31 | 12.40% | $22.65 Million | $182.68 Million | -52.04pp |
| 1999-12-31 | 64.44% | $18.62 Million | $28.89 Million | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodyspla… Read more